Quantcast
Channel: BioTuesdays » phi
Viewing all articles
Browse latest Browse all 7

GeneNews’ IDL to provide prostate testing to MD Anderson

0
0

GeneNews’ (TSX:GEN) Innovative Diagnostic Laboratory (IDL) joint venture has agreed to provide its prostate health index (PHI) testing services to MD Anderson Cancer Center.

Handshake1“There is significant interest in IDL’s early cancer diagnostic tests from hospital groups and large physician practice groups,” said James Howard-Tripp, executive chairman of GeneNews, said in a statement.

“IDL is actively pursuing these opportunities and the signing of MD Anderson to the PHI tests now complements arrangements we have with other institutions,” he said, adding that additional discussions are in progress.

IDL added Beckman Coulter Diagnostics’ FDA-approved and Medicare-reimbursed PHI test to its menu of advanced cancer assays in April 2014. The PHI test is a simple, non-invasive blood test that is three times more specific in detecting prostate cancer than the prostate-specific antigen (PSA) test.

The PHI test helps physicians distinguish prostate cancer from benign conditions by using three different PSA markers (PSA, free PSA and pro2 PSA) as part of a sophisticated calculation to more reliably determine the probability of cancer in patients with elevated PSA levels.


Viewing all articles
Browse latest Browse all 7

Latest Images

Trending Articles





Latest Images